{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:42:06Z","timestamp":1792575726571,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"DOI":"10.1007\/s12185-026-04301-3","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:01:33Z","timestamp":1792573293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current perspectives on high-risk genomic profiles in chronic myeloid leukemia: from bench to clinical practice"],"prefix":"10.1007","author":[{"given":"Mohamed Isam","family":"Sharif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina Maria","family":"Perusini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Sibai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-4911","authenticated-orcid":false,"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"12","key":"4301_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"11","key":"4301_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.20.01659","volume":"39","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli M, Travaglino E, Meggendorfer M, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol. 2021;39(11):1223\u201333.","journal-title":"J Clin Oncol"},{"issue":"14","key":"4301_CR3","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood.2022018896","volume":"141","author":"T Kewan","year":"2023","unstructured":"Kewan T, Bahaj W, Durmaz A, et al. Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes. Blood. 2023;141(14):1768\u201372.","journal-title":"Blood"},{"issue":"16","key":"4301_CR4","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","volume":"141","author":"D Luque Paz","year":"2023","unstructured":"Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141(16):1909\u201321.","journal-title":"Blood"},{"issue":"1","key":"4301_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96(1):145\u201362.","journal-title":"Am J Hematol"},{"issue":"1","key":"4301_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","volume":"129","author":"T Kim","year":"2017","unstructured":"Kim T, Tyndel MS, Kim HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129(1):38\u201347.","journal-title":"Blood"},{"issue":"9","key":"4301_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","volume":"132","author":"S Branford","year":"2018","unstructured":"Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132(9):948\u201361.","journal-title":"Blood"},{"issue":"12","key":"4301_CR8","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","volume":"104","author":"G Nteliopoulos","year":"2019","unstructured":"Nteliopoulos G, Bazeos A, Claudiani S, et al. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica. 2019;104(12):2400\u20139.","journal-title":"Haematologica"},{"issue":"8","key":"4301_CR9","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","volume":"33","author":"S Branford","year":"2019","unstructured":"Branford S, Kim DDH, Apperley JF, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33(8):1835\u201350.","journal-title":"Leukemia"},{"issue":"9","key":"4301_CR10","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.3324\/haematol.2022.282184","volume":"108","author":"N Shanmuganathan","year":"2023","unstructured":"Shanmuganathan N, Wadham C, Shahrin NH, et al. Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica. 2023;108(9):2380\u201395.","journal-title":"Haematologica"},{"issue":"23","key":"4301_CR11","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1182\/blood.2025030259","volume":"146","author":"N Shanmuganathan","year":"2025","unstructured":"Shanmuganathan N, Yeung DT, Wadham C, et al. Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Blood. 2025;146(23):2821\u201332.","journal-title":"Blood"},{"issue":"26","key":"4301_CR12","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26):6760\u20138.","journal-title":"Blood"},{"issue":"4","key":"4301_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012;120(4):761\u20137.","journal-title":"Blood"},{"issue":"4","key":"4301_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","volume":"5","author":"RE Clark","year":"2021","unstructured":"Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5(4):1102\u20139.","journal-title":"Blood Adv"},{"issue":"11","key":"4301_CR15","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37(11):2150\u201367.","journal-title":"Leukemia"},{"issue":"8054","key":"4301_CR16","first-page":"733","volume":"639","author":"RJ Osborne","year":"2025","unstructured":"Osborne RJ, et al. Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia. Nature. 2025;639(8054):733\u201340.","journal-title":"Nature"},{"issue":"4","key":"4301_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00667-9","volume":"12","author":"S Adnan Awad","year":"2022","unstructured":"Adnan Awad S, Bruck O, Shanmuganathan N, et al. Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer J. 2022;12(4):69.","journal-title":"Blood Cancer J"},{"issue":"10","key":"4301_CR18","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/bloodadvances.2023012127","volume":"8","author":"MA Perusini","year":"2024","unstructured":"Perusini MA, Zackova D, Kim T, et al. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood Adv. 2024;8(10):2361\u201372.","journal-title":"Blood Adv"},{"issue":"8","key":"4301_CR19","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","volume":"34","author":"A Fabarius","year":"2020","unstructured":"Fabarius A, Kalmanti L, Dietz CT, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34(8):2074\u201386.","journal-title":"Leukemia"},{"issue":"22","key":"4301_CR20","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"127","author":"W Wang","year":"2016","unstructured":"Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127(22):2742\u201350.","journal-title":"Blood"},{"issue":"10","key":"4301_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00742-1","volume":"12","author":"A Bidikian","year":"2022","unstructured":"Bidikian A, Kantarjian H, Jabbour E, et al. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022;12(10):144.","journal-title":"Blood Cancer J"},{"issue":"9","key":"4301_CR22","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","volume":"36","author":"L Schonfeld","year":"2022","unstructured":"Schonfeld L, Rinke J, Hinze A, et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022;36(9):2242\u20139.","journal-title":"Leukemia"},{"issue":"suppl 1","key":"4301_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/blood-2025-73","volume":"146","author":"S Branford","year":"2025","unstructured":"Branford S, Cortes J, Takahashi N, et al. Distinct patterns of mutant ASXL1 over time and their implications for treatment failure and BCR::ABL1 mutation development in newly diagnosed patients with CML-CP treated with asciminib versus investigator-selected TKI in the ASC4FIRST study. Blood. 2025;146(suppl 1):73.","journal-title":"Blood"},{"issue":"13","key":"4301_CR24","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","volume":"76","author":"S Asada","year":"2019","unstructured":"Asada S, Fujino T, Goyama S, Kitamura T. The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci. 2019;76(13):2511\u201323.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"4301_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/cas.70007","volume":"116","author":"N Miyashita","year":"2025","unstructured":"Miyashita N, Onozawa M, Kasahara K, et al. CML with mutant ASXL1 showed decreased sensitivity to TKI treatment via upregulation of the ALOX5-BLTR signaling pathway. Cancer Sci. 2025;116(4):1115\u201325.","journal-title":"Cancer Sci"},{"key":"4301_CR26","unstructured":"Morgenstern Y, Perusini MA, Gupta G, et al. New pattern of emerging somatic mutations in optimal responders following tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. Haematologica. 2025 [in press]."},{"issue":"19","key":"4301_CR27","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","volume":"130","author":"GC Issa","year":"2017","unstructured":"Issa GC, Kantarjian HM, Nogueras Gonzalez G, et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood. 2017;130(19):2084\u201391.","journal-title":"Blood"},{"key":"4301_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","volume":"59","author":"T Kim","year":"2017","unstructured":"Kim T, Tyndel MS, Zhang Z, et al. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Leuk Res. 2017;59:142\u20138.","journal-title":"Leuk Res"},{"issue":"6","key":"4301_CR29","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.leukres.2009.08.032","volume":"34","author":"RL Paquette","year":"2010","unstructured":"Paquette RL, Nicoll J, Chalukya M, et al. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res. 2010;34(6):708\u201313.","journal-title":"Leuk Res"},{"issue":"1","key":"4301_CR30","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","volume":"12","author":"Y Ochi","year":"2021","unstructured":"Ochi Y, Yoshida K, Huang YJ, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun. 2021;12(1):2833.","journal-title":"Nat Commun"},{"issue":"4","key":"4301_CR31","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","volume":"35","author":"S Adnan Awad","year":"2021","unstructured":"Adnan Awad S, Dufva O, Ianevski A, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021;35(4):1087\u201399.","journal-title":"Leukemia"},{"issue":"3","key":"4301_CR32","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41375-022-01508-1","volume":"36","author":"KL Lee","year":"2022","unstructured":"Lee KL, Ko TK, Ng CH, et al. Validation and refinement of a RUNX1 mutation-associated gene expression signature in blastic phase chronic myeloid leukemia. Leukemia. 2022;36(3):892\u20136.","journal-title":"Leukemia"},{"issue":"7191","key":"4301_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110\u20134.","journal-title":"Nature"},{"issue":"3","key":"4301_CR34","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2014-06-581173","volume":"125","author":"PA Beer","year":"2015","unstructured":"Beer PA, et al. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. Blood. 2015;125(3):504\u201315.","journal-title":"Blood"},{"issue":"16","key":"4301_CR35","first-page":"3931","volume":"59","author":"H Nakayama","year":"1999","unstructured":"Nakayama H, Ishimaru F, Avitahl N, et al. Decreases in Ikaros activity correlate with blastic phase in patients with chronic myelogenous leukemia. Cancer Res. 1999;59(16):3931\u20134.","journal-title":"Cancer Res"},{"issue":"7","key":"4301_CR36","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"2","key":"4301_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3324\/haematol.2021.279317","volume":"107","author":"V Krishnan","year":"2022","unstructured":"Krishnan V, Kim DDH, Hughes TP, Branford S, Ong ST. Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica. 2022;107(2):358\u201370.","journal-title":"Haematologica"},{"issue":"8","key":"4301_CR38","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2019002969","volume":"135","author":"S Soverini","year":"2020","unstructured":"Soverini S, Bavaro L, De Benedittis C, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood. 2020;135(8):534\u201341.","journal-title":"Blood"},{"issue":"5","key":"4301_CR39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1101\/gr.147686.112","volume":"23","author":"JB Hiatt","year":"2013","unstructured":"Hiatt JB, Pritchard CC, Salipante SJ, O\u2019Roak BJ, Shendure J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 2013;23(5):843\u201354.","journal-title":"Genome Res"},{"issue":"8","key":"4301_CR40","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/bioinformatics\/btac081","volume":"38","author":"JJF Medeiros","year":"2022","unstructured":"Medeiros JJF, Latypova X, Bharat N, et al. SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data. Bioinformatics. 2022;38(8):2088\u201395.","journal-title":"Bioinformatics"},{"issue":"7647","key":"4301_CR41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733\u20137.","journal-title":"Nature"},{"issue":"4","key":"4301_CR42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41375-023-02117-2","volume":"38","author":"L Han","year":"2024","unstructured":"Han L, Schubert C, Kohler J, et al. Asciminib in combination with ATP-binding pocket tyrosine kinase inhibitors shows synergistic activity HGPinst BCR::ABL1-positive cells in vitro. Leukemia. 2024;38(4):729\u201338.","journal-title":"Leukemia"},{"key":"4301_CR43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024534","author":"J Nangalia","year":"2020","unstructured":"Nangalia J, Mitchell E, Green AR, et al. Clonal haematopoiesis and the natural history of BCR::ABL1-driven chronic myeloid leukaemia. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2024534.","journal-title":"N Engl J Med"},{"key":"4301_CR44","unstructured":"Branford S, Yeung DT, Shanmuganathan N, et al. ASXL1 mutations predict inferior response to frontline asciminib in newly diagnosed chronic phase CML: analysis of the ASC4FIRST trial. Blood. 2024;144(Suppl 1) [ASH Annual Meeting abstract]."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04301-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04301-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04301-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:01:34Z","timestamp":1792573294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04301-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":44,"alternative-id":["4301"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04301-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}